<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">Esophageal cancer</z:e> incidence is increasing and has few treatment options </plain></SENT>
<SENT sid="1" pm="."><plain>In studying receptor tyrosine kinases associated with <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancers</z:e>, we have identified EPHB4 to be robustly overexpressed in cell lines and <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> tissues </plain></SENT>
<SENT sid="2" pm="."><plain>In total, 94 <z:hpo ids='HP_0002860'>squamous cell carcinoma</z:hpo>, 82 <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>, 25 <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, 13 <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo>, and 25 adjacent or unrelated <z:mpath ids='MPATH_458'>normal</z:mpath> esophageal tissues were evaluated by immunohistochemistry </plain></SENT>
<SENT sid="3" pm="."><plain>EPHB4 expression was significantly higher in <z:hpo ids='HP_0000001'>all</z:hpo> the different histologic categories than in adjacent <z:mpath ids='MPATH_458'>normal</z:mpath> tissues </plain></SENT>
<SENT sid="4" pm="."><plain>In 13 esophageal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell lines, 3 of the 9 <z:mp ids='MP_0004207'>SCC</z:mp> cell lines and 2 of the 4 <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> expressed very high levels of EPHB4 </plain></SENT>
<SENT sid="5" pm="."><plain>An increased gene copy number ranging from 4 to 20 copies was identified in a subset of the overexpressing patient samples and cell lines </plain></SENT>
<SENT sid="6" pm="."><plain>We have developed a novel <z:chebi fb="0" ids="16907">4-nitroquinoline 1-oxide</z:chebi> (4-NQO)-induced mouse model of <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> that recapitulates the EPHB4 expression in humans </plain></SENT>
<SENT sid="7" pm="."><plain>A specific small-molecule inhibitor of EPHB4 decreased cell viability in a time- and dose-dependent manner in 3 of the 4 cell lines tested </plain></SENT>
<SENT sid="8" pm="."><plain>The small-molecule inhibitor and an EPHB4 siRNA also decreased cell migration (12%-40% closure in treated vs. 60%-80% in untreated), with decreased phosphorylation of various <z:chebi fb="0" ids="32789">tyrosyl</z:chebi>-containing proteins, EphB4, and its downstream target p125FAK </plain></SENT>
<SENT sid="9" pm="."><plain>Finally, in a xenograft <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> model, an EPHB4 inhibitor abrogated <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> by approximately 60% compared with untreated control </plain></SENT>
<SENT sid="10" pm="."><plain>EphB4 is robustly expressed and potentially serves as a novel biomarker for targeted therapy in <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancers</z:e> </plain></SENT>
</text></document>